Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Ripretinib (Qinlock) is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib. It ranks highly in effectiveness as a third-line or later therapy for GISTs.
• The analysis was derived from three systematic reviews/meta-analyses that provided a detailed comparison of Qinlock's safety and effectiveness against other tyrosine kinase inhibitors (TKIs).
• In terms of progression-free survival (PFS), overall survival (OS), and disease control rate (DCR), ripretinib outperforms other third-line therapies, suggesting it provides significant benefits in delaying disease progression in heavily pretreated GIST patients.
• While one study suggested nilotinib and pimitespib had slightly better tolerability based on SUCRA statistics, ripretinib, alongside masitinib, were indicated to likely have the lowest rates of severe adverse events among the analyzed drugs. This suggests a favorable balance between its effectiveness and tolerability.
• Despite some findings recommending regorafenib due to higher perceived reliability, it has been noted that this drug has the highest incidence of high-grade adverse events among comparators which contradicts its recommendation over ripretinib.
• Regarding health-related quality of life outcomes amongst various TKIs including ripretinib; while all TKIs are associated with common adverse effects, those treated with Qinlock experienced stable HRQoL similar to first-line treatments like imatinib but potentially more favorable when compared to sunitinib.